Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-collagen VII peptide
- Development stage
- Preclinical
- Lead developer
- Intract Pharma
- Modality
- Peptides
- Administration
- Oral
01
Overview
Anti-collagen VII peptide is a preclinical-stage therapeutic peptide being developed by Intract Pharma for the treatment of ulcerative colitis. The drug is designed to target collagen VII, a major component of anchoring fibrils in the basement membrane of the colonic mucosa. By targeting collagen VII, the peptide aims to address mucosal healing and structural integrity in the gastrointestinal tract of patients with inflammatory bowel disease (IBD).
02
Targets
COL7A1 (Collagen type VII alpha 1 chain)
Beyond the preview
Go deeper on anti-collagen VII peptide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-collagen VII peptide.